IO Biotech ( ($IOBT) ) has issued an update. IO Biotech, Inc. faced a compliance issue with Nasdaq’s minimum bid price requirement when its stock ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Enrollment in the three ongoing company-sponsored clinical trials is now complete. The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying ...

IO Biotech (NASDAQ:IOBT) has filed for the sale of up to 5.6M shares of common stock for holders. Filing IO Biotech GAAP EPS of -$0.34 beats by $0.11 Seeking Alpha’s Quant Rating on IO Biotech ...

Get the annual and quarterly balance sheets for IO Biotech, Inc. (IOBT) including details of assets, liabilities and shareholders’ equity.

OpenAI is acquiring io, the device startup that CEO Sam Altman and famed Apple designer Jony Ive have quietly been working on for two years, in an all-equity deal that values that startup at $6.5 ...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, ...